Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists

Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists

Abstract Background Anti‐obesity medications (AOMs) have historically had limited weight‐loss efficacy. However, newer glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA)–based therapies seem to be more effective, including dual agonists of GLP‐1R and the glucagon receptor (GCGR) or glucose‐dependen...

Full description

Bibliographic Details
Main Authors: W. Timothy Garvey, Cathy D. Mahle, Trevor Bell, Robert F. Kushner
Format: Article
Language:English
Published: Wiley 2024-06-01
Series:Obesity Science & Practice
Subjects:
anti‐obesity agents
glucagon
glucagon‐like peptide‐1
glucose‐dependent insulinotropic polypeptide
health care surveys
obesity
Online Access:https://doi.org/10.1002/osp4.756

Similar Items

Similar Items